Cost-Effectiveness of Second-Line Chemotherapy for Non small Cell Lung Cancer. An Economic, Randomized, Prospective, Multicenter Phase III Trial Comparing Docetaxel and Pemetrexed (GFPC 05-06 Study)

 

[pdf]J Thorac Oncol 2011;6:161[/pdf]